Researchers Discover Potential Therapy for Triple-Negative Breast Cancer

  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 31 sec. here
  • 11 min. at publisher
  • 📊 Quality Score:
  • News: 47%
  • Publisher: 71%

Health News

Research,Therapy,Triple-Negative Breast Cancer

Researchers at Baylor College of Medicine have identified a potential therapy for triple-negative breast cancer (TNBC) by targeting the protein eIF4A with a small molecule drug called Zotatifin. The drug not only suppresses tumor cell proliferation but also remodels the tumor immune microenvironment, leading to improved outcomes. Clinical trials are now being considered to assess the potential benefits of this approach.

Reviewed by Lily Ramsey, LLMOct 30 2023 Responding to this need for better treatments, researchers at Baylor College of Medicine and collaborating institutions have investigated potential vulnerabilities in TNBC that could lead to novel therapies and improved outcomes for this devastating condition.

The results are encouraging. Treatment with Zotatifin not only reduced tumor size in animal models, but also stimulated an interferon response, which improved the immune microenvironment of the tumor. "This is important for effective tumor elimination," said Rosen, Distinguished Service Professor of molecular and cellular biology and member of the Dan L Duncan Comprehensive Cancer Center at Baylor. He also is the corresponding author of the work. "TNBC tumors are typically 'cold tumors,' meaning they have more immune cells that protect the tumor than cells that fight the tumor.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 19. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

FDA approves mirikizumab for induction and maintenance therapyThe FDA has approved mirikizumab as a treatment for induction and maintenance therapy in certain patients.
Source: medical_xpress - 🏆 101. / 51 Read more »